Megan Olsen, MPH, principal at Avalere, explores the challenges that arise for Medicaid plans when providers choose to prescribe a cell or gene therapy.
Megan Olsen, MPH, principal at Avalere, explores the challenges that arise for Medicaid plans when providers choose to prescribe a cell or gene therapy.
Transcript
What challenges do Medicaid plans need to overcome when choosing to provide gene and cell therapies and what has CMS done to address them?
Yeah, that's a good question. The cell and gene therapy space is very interesting when you think about it through a Medicaid lens. On one hand, with a lot of these gene therapies in particular that treat rare pediatric conditions, you're going to have a lot of Medicaid patients. So, Medicaid is going to be acutely impacted on a population basis, given they enroll a lot of children. They cover a lot of children.
On the other hand, states are also more limited in the types of innovative arrangements that they can enter or the resources that they have to dedicate to these treatments. States have fixed budgets, they need to balance their budgets annually, so there are some some limitations there. We've seen some interest of merge among states and we've been doing a lot of tracking of how states are adapting to this early wave of cell and gene therapies relative to what's coming down the pipeline and how they might need to adjust going forward. But one of the early indicators is that we've seen over the past couple of years growing state interest in value-based contracting arrangements and getting state plan amendment approval from CMS. It's not something that's been applied as much in the cell and gene therapy space yet today but I think as more products enter the market, there will likely be growing interest in new ways for states to pay for these types of treatments.
We've also seen states think about how to develop coverage policies around these therapies and one of the things that that we've highlighted is that, in many cases, some states have been slow or not developing transparent health coverage policies for these treatments, and are rather leaving it up to medical director decision in reviewing on a one-off basis for medical necessity.
More broadly, there is a conversation emerging at the federal level around what is the best way to cover and finance cell and gene therapies in the Medicaid program, and we saw [the Medicaid and CHIP Payment and Access Commission] recently and on an ongoing basis, they're continuing to explore new ways to cover and finance cell and gene therapies in particular, potentially through a new federal benefit that carves out cell and gene therapies from the Medicaid drug rebate program and applies differential coverage and rebate structures to it. So, I think that is in the early stages of discussion, but I think that underscores the point that there is a lot of thinking and a lot of work to be done as it relates to cell and gene therapies in the Medicaid market moving forward.
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More